QAAGZX Performance — T. Rowe Price Health Sciences Portfolio
Data updated: 2026-08-27
QAAGZX returned +7.28% year to date and +30.42% over one year to Jun 2026. Annualised returns are +9.52% over 3 years and +3.71% over 5 years. The fund trailed its Health Care Equity category average: $100 invested three years ago grew to $131, against $138 for the category, and to $130 over one year, against $137. Volatility over the past three years was 15.29% a year. In the 12 months to Jun 2026 the fund lost a net $34.0M, and assets reached $751.71M.
QAAGZX Growth of $100
What $100 invested in T. Rowe Price Health Sciences Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | QAAGZX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $130 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $131 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $120 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $187 | $182 |
QAAGZX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +7.28% |
| 1 year | +30.42% |
| 3 years (annualised) | +9.52% |
| 5 years (annualised) | +3.71% |
QAAGZX Annual Returns
Calendar-year total returns of T. Rowe Price Health Sciences Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +7.28% |
| 2025 | +18.10% |
| 2024 | +1.66% |
| 2023 | +2.96% |
| 2022 | −12.46% |
| 2021 | +13.11% |
| 2020 | +29.60% |
| 2019 (Jul–Dec) | +9.60% |
QAAGZX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.0% | +0.7% | −5.9% | +1.6% | +3.6% | +8.8% | — | — | — | — | — | — |
| 2025 | +6.2% | −1.8% | −4.1% | −0.1% | −6.4% | +4.0% | −1.3% | +4.2% | +2.3% | +8.0% | +9.2% | −1.9% |
| 2024 | +2.0% | +4.0% | +1.6% | −5.0% | +2.3% | +2.8% | +2.7% | +5.2% | −2.0% | −5.0% | +1.5% | −7.7% |
| 2023 | +0.6% | −4.7% | +1.9% | +3.5% | −3.0% | +2.8% | −0.1% | −1.5% | −3.9% | −3.9% | +5.5% | +6.3% |
| 2022 | −12.4% | −0.4% | +4.7% | −8.6% | −0.9% | −0.6% | +5.5% | −3.1% | −4.3% | +7.6% | +4.1% | −3.0% |
| 2021 | +2.4% | −1.8% | −0.7% | +4.9% | −0.9% | +5.5% | +2.0% | +4.1% | −4.6% | +4.2% | −4.9% | +3.0% |
| 2020 | −2.6% | −4.3% | −7.3% | +13.9% | +7.6% | +0.7% | +3.2% | +1.8% | +1.7% | −1.1% | +10.1% | +4.6% |
| 2019 | — | — | — | — | — | — | −1.3% | −2.9% | −3.7% | +6.5% | +8.5% | +2.8% |
QAAGZX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 15.29%
- 3-year Sharpe ratio: 0.33 (vs 4.5% risk-free rate)
- Best month: +9.16% (Nov 2025)
- Worst month: −7.66% (Dec 2024)
QAAGZX Fund Flows
Monthly money in and out of T. Rowe Price Health Sciences Portfolio, from SEC Form N-PORT.
- 12-month net flow: −$34.0M
- 12-month gross sales (incl. reinvestments): $111.0M
- Sales ÷ redemptions: 0.77×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $8.3M | $10.1M | −$1.8M |
| May 2026 | $9.7M | $13.4M | −$3.7M |
| Apr 2026 | $10.1M | $10.0M | $123K |
| Mar 2026 | $4.8M | $10.4M | −$5.6M |
| Feb 2026 | $6.0M | $9.5M | −$3.4M |
| Jan 2026 | $9.0M | $22.2M | −$13.2M |
| Dec 2025 | $32.4M | $12.7M | $19.6M |
| Nov 2025 | $4.9M | $7.2M | −$2.3M |
| Oct 2025 | $3.8M | $9.2M | −$5.4M |
| Sep 2025 | $3.6M | $10.7M | −$7.0M |
| Aug 2025 | $5.1M | $21.4M | −$16.4M |
| Jul 2025 | $13.1M | $8.0M | $5.2M |
QAAGZX Assets Under Management
Net assets of T. Rowe Price Health Sciences Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $751.71M |
| 2026-03-31 | $662.62M |
| 2025-12-31 | $729.78M |
| 2025-09-30 | $644.44M |
| 2025-06-30 | $630.97M |
| 2025-03-31 | $660.11M |
| 2024-12-31 | $665.57M |
| 2024-09-30 | $755.61M |
| 2024-06-30 | $718.98M |
| 2024-03-31 | $739.65M |
| 2023-12-31 | $702.46M |
| 2023-09-30 | $664.66M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.